

# Pancreatic Cancer (Adenocarcinoma) Pathways

---

Patient Name: \_\_\_\_\_

Date of Birth: \_\_\_\_\_

Member Number: \_\_\_\_\_

Treatment Start Date: \_\_\_\_\_

Pathology: \_\_\_\_\_

Stage: \_\_\_\_\_

Line of Therapy: \_\_\_\_\_

ICD-10 Code: \_\_\_\_\_

## Adjuvant Therapy

- Stages I, IA, IB, II, IIA, IIB, and III
  - Capecitabine (Xeloda) and gemcitabine (Gemzar)
  - FULV**: fluorouracil (5FU) and leucovorin
  - Gemcitabine (Gemzar)
  - mFOLFIRINOX\***: fluorouracil (5FU), leucovorin, irinotecan (Camptosar), and oxaliplatin

## First Line of Therapy (1<sup>st</sup> Line)

- Stages III, IV, and Recurrent
  - FOLFIRINOX**: fluorouracil (5FU), leucovorin, irinotecan (Camptosar), and oxaliplatin
  - mFOLFIRINOX**: fluorouracil (5FU), leucovorin, irinotecan (Camptosar), and oxaliplatin
  - Gemcitabine (Gemzar)
  - Gemcitabine (Gemzar) and albumin-bound-paclitaxel (Abraxane)

---

\* Modified FOLFIRINOX: Bolus 5-FU not administered and dose of Irinotecan 150mg/m<sup>2</sup>

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars of reference products listed are considered "on pathway." However, reimbursement for biosimilar products may be impacted by health plan specific formularies, medical policy and preferred product rules.



8600 West Bryn Mawr Avenue  
South Tower – Suite 800 Chicago, IL 60631

Last review: 11/7/2023 | Effective date: 2/5/2024

© 2024 Carelon Medical Benefits Management